Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Analyst recommendations
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Sign up for Trump’s Return Updated at 4:55 p.m. ET on January 20, 2025 Eight years ago, with his “American carnage” speech, Donald Trump delivered what...
Trump’s MAGA nostalgia for an earlier age of American power and prosperity was solidified by the president’s praise for William McKinley, ostensibly for the 25th president’s support for tariffs ...
Hennion & Walsh Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 33.4% during the 4th quarter, according to its most recent Form 13F ...